SANA vs. NVAX, DNA, BEAM, FUSN, CGON, INBX, VCYT, ADMA, HRMY, and KYMR
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Novavax (NVAX), Ginkgo Bioworks (DNA), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), CG Oncology (CGON), Inhibrx (INBX), Veracyte (VCYT), ADMA Biologics (ADMA), Harmony Biosciences (HRMY), and Kymera Therapeutics (KYMR). These companies are all part of the "medical" sector.
Sana Biotechnology (NASDAQ:SANA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, community ranking, profitability, institutional ownership, valuation and earnings.
Sana Biotechnology has a net margin of 0.00% compared to Novavax's net margin of -40.01%. Novavax's return on equity of 0.00% beat Sana Biotechnology's return on equity.
Novavax received 830 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 74.12% of users gave Novavax an outperform vote while only 50.00% of users gave Sana Biotechnology an outperform vote.
Sana Biotechnology has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 34.9% of Sana Biotechnology shares are owned by insiders. Comparatively, 0.9% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Sana Biotechnology has higher earnings, but lower revenue than Novavax. Sana Biotechnology is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Sana Biotechnology currently has a consensus price target of $11.67, indicating a potential upside of 33.64%. Novavax has a consensus price target of $14.00, indicating a potential upside of 7.61%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Novavax.
In the previous week, Novavax had 36 more articles in the media than Sana Biotechnology. MarketBeat recorded 40 mentions for Novavax and 4 mentions for Sana Biotechnology. Novavax's average media sentiment score of 0.52 beat Sana Biotechnology's score of 0.46 indicating that Novavax is being referred to more favorably in the news media.
Summary
Novavax beats Sana Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
